Active	Status	Sponsor type	Region	Phase	Filter
13 Active 4 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chen, Xiaohong
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma	Recruiting	4	360	RoW	Anlotinib Hydrochloride Capsule	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Medullary Thyroid Cancer	06/27	12/28
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
Zhang, Hongying
NCT05582629: JT001 (VV116) for the Treatment of COVID-19	Completed	3	1369	RoW	JT001, VV116, Placebo	Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH	Mild to Moderate COVID-19	02/23	02/23
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.	Recruiting	N/A	244	RoW	Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders	Lifetech Scientific (Shenzhen) Co., Ltd.	Patent Foramen Ovale, Cryptogenic Stroke	04/25	06/29
Yang, Fuping
No trials found
Lin, Minggui
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Chen, Xiaohong
NCT05830500: Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma	Recruiting	4	360	RoW	Anlotinib Hydrochloride Capsule	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Medullary Thyroid Cancer	06/27	12/28
LIBRETTO-531, NCT04211337 / 2019-001978-28: A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer	Active, not recruiting	3	291	Europe, Canada, Japan, US, RoW	Selpercatinib, LY3527723, LOXO-292, Cabozantinib, Vandetanib	Loxo Oncology, Inc., Eli Lilly and Company	Medullary Thyroid Cancer	05/23	02/26
Zhang, Hongying
NCT05582629: JT001 (VV116) for the Treatment of COVID-19	Completed	3	1369	RoW	JT001, VV116, Placebo	Shanghai Vinnerna Biosciences Co., Ltd., Sponsor GmbH	Mild to Moderate COVID-19	02/23	02/23
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.	Recruiting	N/A	244	RoW	Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders	Lifetech Scientific (Shenzhen) Co., Ltd.	Patent Foramen Ovale, Cryptogenic Stroke	04/25	06/29
Yang, Fuping
No trials found
Lin, Minggui
No trials found